For instance, PBMCs were harvested for cellular therapy and CTL were generated directed against autologous (glioma) tumor cells (using a mix of PBMCs, autologous tumor cells and recombinant IL-2), followed by in situ administration (108 up to 109 T-cells i.t.). This evidence concerns the gene IL2 and neoplasm.